Business Wire

MA-EXAGRID

Share
ExaGrid Reports Record Bookings and Revenue for Q2 2019

ExaGrid ® , a leading provider of intelligent hyperconverged storage for backup with data deduplication, today announced record bookings and revenue for the quarter’s end in June 2019. ExaGrid posted the best quarter in its history and is on path to post another record bookings and revenue year.

“This was our best bookings and revenue quarter in the history of the company,” said Bill Andrews, CEO and President of ExaGrid. “We had a record number of six-and-seven-figure new customer deals in the quarter, which is a trend that continues to build as we gain momentum in large organizations globally.”

In addition to record Q2 bookings and revenue, ExaGrid achieved the following:

  • ExaGrid is expanding support in Chile, Switzerland, India, Indonesia and other countries. ExaGrid has sales staff all over the world including Argentina, Australia, Benelux, Brazil, Canada, Colombia, Czech Republic, Dubai, France, Germany, Hong Kong, Israel, Italy, Mexico, Nordics, Poland, Singapore, South Africa, South Korea, Spain, Taiwan, Turkey, United Kingdom, United States and many others.
  • ExaGrid has built upon its strong strategic alliance partner relationships with Veeam Software, HYCU and Zerto. The expanded relationship with HYCU allows for further penetration into organizations deploying Nutanix with ESXi and AHV.
  • Enhanced functionality allowing Commvault deduplication to remain turned on so that appliances behind can further deduplicate Commvault data by an additional 3X, which greatly reduces storage costs. ExaGrid is gaining momentum with Commvault customers.
  • Voted Storage Magazine’s “Enterprise Backup Hardware Product of the Year” at its annual awards ceremony Storries XVI.

As the market matures, organizations realize the performance degradation that data deduplication can have on backup unless a solution is intentionally architected to prevent any such impact. All deduplication solutions reduce storage and WAN bandwidth to a degree, but only ExaGrid solves the three inherent compute problems to achieve faster backups, restores, and VM boots by leveraging its unique Landing Zone, Adaptive Deduplication, and scale-out architecture.

“First-generation deduplication solutions can be cost prohibitive for backup storage and are slow for backups, restores, and VM boots, which is why over 80% of ExaGrid’s newly-acquired customers are replacing Dell EMC Data Domain, HPE StoreOnce, and the Veritas NetBackup 5200/5300 series of appliances. We are replacing low cost primary storage disk behind Commvault, as ExaGrid is far less expensive than Cisco 3260, NTAP eSeries, HPE Nimble, Dell, etc. when customers require longer term retention,” Andrews said.

All backup storage vendors reduce storage and bandwidth to varying degrees, but most provide slow ingest rates due to deduplication being performed ‘inline.’ Additionally, other solutions only store deduplicated data, which causes restore speeds and VM boots to be very slow. ExaGrid’s ingest rate is 6X faster than its closest competitor. Unlike the first-generation vendors that only add capacity as data grows, ExaGrid appliances add compute with capacity, ensuring that the backup window remains fixed in length. Only ExaGrid uses a scale-out architecture with a unique loading zone, which holistically addresses all of the scalability and performance challenges of backup storage.

ExaGrid’s turnkey disk-based backup system combines enterprise storage with zone-level data deduplication, delivering a disk-based solution that is far more cost effective than low cost disk. Unlike first-generation inline/scale-up deduplication solutions that were either built into a backup application media server or into a dedicated storage appliance, ExaGrid delivers the backup industry’s only true landing zone and scale-out architecture with data deduplication. Utilizing ExaGrid’s landing zone with adaptive deduplication, typically halves the cost of the first-generation large brand solutions and is 3X the backup performance and 20X the restore/VM boot performance. By using a scale-out architecture, ExaGrid is the only solution that keeps the backup window fixed in length as data grows and eliminates both forklift upgrades and forced product obsolescence.

ExaGrid’s published customer success stories and enterprise stories number over 360, more than all other vendors in the space combined. These stories demonstrate how satisfied customers are with ExaGrid’s unique architectural approach, differentiated product, and unrivaled customer support. Customers consistently state that not only is the product best-in-class, but ‘it just works.’

About ExaGrid
ExaGrid provides intelligent hyperconverged storage for backup with data deduplication, a unique landing zone, and scale-out architecture. ExaGrid’s landing zone provides for the fastest backups, restores, and instant VM recoveries. Its scale-out architecture includes full appliances in a scale-out system and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades. Visit us at exagrid.com or connect with us on LinkedIn . See what our customers have to say about their own ExaGrid experiences and why they now spend significantly less time on backup in our customer success stories .

ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release

First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye